前收市價 | 6.75 |
開市 | 6.60 |
買盤 | 6.09 x 100 |
賣出價 | 6.14 x 600 |
今日波幅 | 6.05 - 6.88 |
52 週波幅 | 1.57 - 7.66 |
成交量 | |
平均成交量 | 642,055 |
市值 | 320.96M |
Beta 值 (5 年,每月) | 無 |
市盈率 (最近 12 個月) | 無 |
每股盈利 (最近 12 個月) | -1.88 |
業績公佈日 | 2024年8月09日 - 2024年8月13日 |
遠期股息及收益率 | 無 (無) |
除息日 | 無 |
1 年預測目標價 | 12.80 |
Black Diamond Therapeutics (BDTX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Black Diamond (BDTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
The average of price targets set by Wall Street analysts indicates a potential upside of 129.3% in Black Diamond (BDTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.